Xestoquinone is a polycyclic
quinone-type metabolite with a reported antitumor effect. We tested the cytotoxic activity of
xestoquinone on a series of hematological
cancer cell lines. The antileukemic effect of
xestoquinone was evaluated in vitro and in vivo. This marine metabolite suppressed the proliferation of Molt-4, K562, and Sup-T1 cells with IC50 values of 2.95 ± 0.21, 6.22 ± 0.21, and 8.58 ± 0.60 µM, respectively, as demonstrated by MTT assay. In the cell-free system, it inhibited the activity of
topoisomerase I (
Topo I) and II (
Topo II) by 50%
after treatment with 0.235 and 0.094 μM, respectively. The flow cytometric analysis indicated that the cytotoxic effect of
xestoquinone was mediated through the induction of multiple apoptotic pathways in Molt-4 cells. The pretreatment of Molt-4 cells with N-acetyl
cysteine (NAC) diminished the disruption of the mitochondrial membrane potential (
MMP) and apoptosis, as well as retaining the expression of both
Topo I and II. In the nude mice xenograft model, the administration of
xestoquinone (1 μg/g) significantly attenuated
tumor growth by 31.2% compared with the
solvent control. Molecular docking, Western blotting, and thermal shift assay verified the catalytic inhibitory activity of
xestoquinone by high binding affinity to HSP-90 and
Topo I/II. Our findings indicated that
xestoquinone targeted
leukemia cancer cells through multiple pathways, suggesting its potential application as an antileukemic
drug lead.